Smart Technology Facilitated Patient-centered Care for Patients With Pulmonary Thromboembolism

Sponsor
Navy General Hospital, Beijing
Study ID
NCT06382038
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Digital Health
  • Pulmonary Thromboembolisms
  • Venous Thromboembolism

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • mobile venous thromboembolism application (mVTEA) — OTHER
    mVTEA will assist in the management of patients during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends venous thromboembolism (VTE)-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, voice, and video communication.

Study Details

Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention. The objective of this study is to evaluate the impact of mobile venous thromboembolism application (mVTEA) based patient-centered management of pulmonary thromboembolism (PTE) on the long-term outcome of PTE patients, in order to enhance clinical practice and establish a foundation of evidence for managing patients with PTE.

Key Dates

First listed
Apr 24, 2024
Start date
Oct 8, 2025
Status verified
May 2025
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
2,972 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: mVTEA Management Group
    Patients randomly assigned to the mVTEA management group will be discharged with mVTEA-assisted patient-centered PTE management.
  • No Intervention: Routine Management Group
    Patients randomly assigned to the routine management group will be given routine post-discharge management in accordance with local clinical practice.

Primary Outcome Measure

VTE-related composite event [ Time Frame: At 1-year follow-up ]

Central Contacts

Related Studies